All In Biotech

Drug Trial Radar · NCT06806592

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

A Double Blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nerandomilast Over at Least 26 Weeks in Patients With Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases (SARD-ILD)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 414 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

414

Actual

Start

Sep 13, 2025

Primary completion

Apr 15, 2027

Study completion Apr 28, 2027

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improvement in lung function after standard treatment with immunosuppressant medicine. The main purpose of this study is to find out how a medicine called nerandomilast affects the lungs in people with systemic autoimmune rheumatic disease. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet 2 times a day for at least 26 weeks and up to 1 year. Participants continue immunosuppressant treatment for their underlying rheumatic disease. Participants are in the study for about 7.5 to 13 months depending on when they join the study. During this time, they visit the study site about 9 to 10 times. At study visits, participants have lung function tests. At select visits, chest imaging is performed. Participants fill in questionnaires about their symptoms and quality of life. The results between the 2 groups are compared to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Interstitial Lung Diseases
  • Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

Interventions

  • NerandomilastDrug

    Nerandomilast

  • Placebo matching nerandomilastDrug

    Placebo matching nerandomilast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change from baseline in quantitative interstitial lung disease (QILD) score [%] on high-resolution computed tomography (HRCT) at Week 26Time frame: At baseline and at Week 26

Locations

153 sites in 16 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic-Arizona

    Scottsdale, Arizona

  • University of California Los Angeles

    Los Angeles, California

  • Paradigm Clinical Research - San Diego

    San Diego, California

  • National Jewish Health

    Denver, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • Meris Clinical Research-Brandon-69466

    Brandon, Florida

  • Miami VA Healthcare System

    Miami, Florida

  • Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead

    Atlanta, Georgia

  • Augusta University

    Augusta, Georgia

  • Northwestern University

    Chicago, Illinois

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Northshore University Health System

    Evanston, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic, Rochester

    Rochester, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Northwell Health

    Great Neck, New York

  • NYU Langone Health

    New York, New York

  • New York Presbyterian Hospital -Columbia University

    New York, New York

  • Onsite Clinical Solutions

    Salisbury, North Carolina

  • Southeastern Research Center-Winston Salem-69289

    Winston-Salem, North Carolina

  • Temple Lung Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • The University of Texas Health Science Center at Houston

    Houston, Texas

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • University of Utah Health Sciences Center

    Salt Lake City, Utah

  • Rheumatology and Pulmonary Clinic

    Beckley, West Virginia

  • University of Wisconsin

    Madison, Wisconsin

  • Royal Prince Alfred Hospital

    Camperdown, Sydney, New South Wales, Australia

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • The Prince Charles Hospital

    Chermside, Queensland, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Krems University Hospital

    Krems, Austria

  • Klinikum Wels - Grieskirchen GmbH

    Wels, Austria

  • Beijing Chao-Yang Hospital

    Beijing, China

  • China-Japan Friendship Hospital

    Beijing, China

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.